#10
JRP
1/29/87

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Kohl et al

Serial No.: 748,591

Filed: June 14, 1985

For: DIALKOXYPYRIDINES, PROCESSES FOR THEIR PREPARATION, THEIR USE AND MEDICAMENTS CONTAINING THEM

Group Art Unit: 121

Examiner: Jane T. Fan

Honorable Commissioner of Patents
and Trademarks
Washington, D. C. 20231

January 22, 1987

Sir:

DECLARATION UNDER RULE 132

I, Uwe Krüger, being duly warned, declare and say:

1. THAT, I am a citizen of the Federal Republic of Germany, residing at Neuhauserstrasse 11, D-7750 Konstanz, Federal Republic of Germany.

THAT, from April 1959 to September 1964, I studied Chemistry (physical Chemistry with Mathematics and Nuclear-Chemistry as subsidiary subjects) at the Technical University of Braunschweig and, from August 1963 to September 1964, I did the practical work (electron diffraction at molecular gases) required for the degree of 'Diplom-Chemiker' (corresponding to the master degree) at the Physikalisch Technische Bundesanstalt in Braunschweig-Völkenrode. From September 1964 to November 1966, as a scientific assistant in the department of molecular spectroscopy at the Organic Chemical Institute of the Technical Universi-

ty of Braunschweig, I worked out my Thesis (initial Lewis acid complexes in Friedel-Craft reactions) and received the degree of Doctor (Dr. rer. nat.) at the end of this period. Post doctoral research (Nuclear Magnetic Resonance) followed with the Gesellschaft für Biotechnologische Forschung at Stöckheim until December 1969. From February 1970 to December 1973, I worked as a member of the scientific staff of the Philips Research Lab. in Hamburg in the field of Kerr liquids and Photochemistry.

THAT, in January 1974 I joined Byk Gulden Lomberg Chemische Fabrik GmbH, Constance, a pharmaceutical company, and, at present, I hold the position of the Head of the Department of Physical Organic Chemistry.

THAT, I have a 23 years experience in Physical Chemistry and good knowledge of Organic Chemistry.

THAT, I am the author and coauthor of numerous scientific publications including those on the attachment hereto.

2. THAT, with regard to structural and stability problems, I am fully conversant with the class of compounds of substituted 2-(2-pyridylmethylsulfinyl)-benzimidazoles as described and claimed, for example, in U.S. patent application SN 748,591 and U.S. patents no. 4,255,431, 4,555,518 and 4,560,693.

THAT, the degradation of substituted 2-(2-pyridylmethylsulfinyl)-benzimidazoles is a known problem. Such degradation can be observed, for example, on storage as a solid (cf. U.S. patent 4,544,750, column 1, line 55), or in solution, in particular in an acidic environment (cf. U.S. patent 4,472,409, column 2, line 40), which leads to proton induced activation of the substance and rearrangement to its active principle [1, 2].

THAT, one of the main objects of the invention described and claimed in U.S. patent application SN 748,591 (cf. page 2, line 18) is to provide new 2-(2-pyridylmethylsulfinyl)-benzimidazoles which have, as compared with the 2-(2-pyridylmethylsulfinyl)-benzimidazoles known from the prior art, a higher chemical stability under those conditions, where a proton induced activation and rearrangement of the substance is not desired (i.e. under neutral conditions down to a pH of 5), such higher chemical stability being expected to correlate with the occurrence of less side effects.

P.51 line 13

3. THAT, comparative tests, which were made in order to compare the stability of the compounds of SN 748,591 with the stability of the compounds of U.S. patents no. 4,255,431, 4,555,518 and 4,560,693, and which are described on the following pages in more detail, were performed in the laboratories of Byk Gulden Lomberg Chemische Fabrik GmbH, Konstanz, under my supervision and direction.

Comparative Tests

Compounds

The following compounds of U.S. patent application SN 748,591 (A) and U.S. patents no. 4,255,431 (B), 4,555,518 (C) and 4,560,693 (D) listed in Table 1 have been investigated in the comparative tests:

does not have to compare

Table 1

Compound No.	Origin	Name
1	C	2-[(4-Methoxy-3-methyl-2-pyridyl)methylsulfinyl]-5-(1,1,2,2-tetrafluoroethoxy)-1H-benzimidazole
2	A	2-[(3,4-Dimethoxy-2-pyridyl)methylsulfinyl]-5-(1,1,2,2-tetrafluoroethoxy)-1H-benzimidazole
~~3~~	~~B~~	5-Methoxy-2-[(4-methoxy-3-methyl-2-pyridyl)methylsulfinyl]-1H-benzimidazole
4	C	5-Difluoromethoxy-2-[(4-methoxy-3-methyl-2-pyridyl)methylsulfinyl]-1H-benzimidazole
5	A	5-Difluoromethoxy-2-[(3,4-dimethoxy-2-pyridyl)methylsulfinyl]-1H-benzimidazole
6	C	5-Difluoromethoxy-6-methoxy-2-[(4-methoxy-3-methyl-2-pyridyl)methylsulfinyl]-1H-benzimidazole
7	A	5-Difluoromethoxy-6-methoxy-2-[(3,4-dimethoxy-2-pyridyl)methylsulfinyl]-1H-benzimidazole
8	D	2,2-Difluoro-6-[(4-methoxy-3-methyl-2-pyridyl)methylsulfinyl]-5H-[1,3]-dioxolo[4,5-f]benzimidazole
9	A	2,2-Difluoro-6-[(3,4-dimethoxy-2-pyridyl)methylsulfinyl]-5H-[1,3]-dioxolo[4,5-f]benzimidazole
10	C	2-[(4-Methoxy-3-methyl-2-pyridyl)methylsulfinyl]-5-(2,2,2-trifluoroethoxy)-1H-benzimidazole
11	A	2-[(3,4-Dimethoxy-2-pyridyl)methylsulfinyl]-5-(2,2,2-trifluoroethoxy)-1H-benzimidazole
~~12~~	~~B~~	2-[(4-Methoxy-3,5-dimethyl-2-pyridyl)methylsulfinyl]-5-methoxy-1H-benzimidazole
13	A	2-[(4,5-Dimethoxy-3-methyl-2-pyridyl)methylsulfinyl]-5-difluoromethoxy-1H-benzimidazole
14	C	2-[(4-Methoxy-5-methyl-2-pyridyl)methylsulfinyl]-5-(1,1,2,2-tetrafluoroethoxy)-1H-benzimidazole
15	A	2-[(4,5-Dimethoxy-2-pyridyl)methylsulfinyl]-5-(1,1,2,2-tetrafluoroethoxy)-1H-benzimidazole

Objective

The gastric hydrochloric acid is produced in the parietal cells which are located in mucosal glands in the body and fundus of the stomach. The enzyme which regulates the production of hydrochloric acid in the parietal cells is the (H^+-K^+)-ATPase which therefore can be regarded as the proton pump in the secretory membrane of parietal cells. The inhibitory action of substituted 2-(2-pyridylmethyl-sulfinyl)-benzimidazoles on gastric acid secretion has to be attributed to inhibition of the (H^+-K^+)-ATPase.

Previous studies [1, 2] on the mode of action of this class of compounds have shown that their (H^+-K^+)-ATPase inhibiting activity is based on an acid induced transformation generating a highly thiophilic intermediate, which inhibits the (H^+-K^+)-ATPase by reaction with an essential SH-group of this enzyme. This acid activated transformation preferably should take place at a pH of 1-2, the pH of the acidic compartment of the parietal cell.

Since any reactions of the thiophilic intermediate with enzymatic SH-groups outside of the parietal cell could cause unwanted and unspecific side effects, acid activation should not or only to a small amount take place at those pH values which can be found **outside** the parietal cells.

Therefore, reactivity of the compounds should be as low as possible not only at the neutral pH (e.g. in the blood) but also at a pH down to the range of 5, which is reported for the lysosomes [3, 4], the cytoplasmic organelles in the body which enclose an acidic environment containing numerous enzymes capable of hydrolyzing most biological macromolecules. It was the objective of the invention described and claimed in U.S. patent application SN. 748,591 to improve the specificity by reducing the reactivity at neutral pH down to a limit of pH 5. The stability in solution at pH 5 was used as the appropriate criterion for the selection of optimised structures which are still sufficiently reactive at pH < 2 and highly active in (H^+-K^+)-ATPase inhibition.

Method

For determining the chemical stability as a measure for reactivity, the compounds to be investigated are dissolved in a 1:3 mixture of CH_3CN/H_2O (with addition of 0.01 M KH_2PO_4). The pH is adjusted to 5 with phosphoric acid. The addition of CH_3CN is needed for solubility reasons. The (pseudo first order) de-

cay of the compound is monitored by repeated HPLC (High Pressure Liquid Chromatography) analysis over a period of at least one half-life. Half-lives are calculated from concentration-time data by linear regression.

Results

The stability data, which resulted when the compounds of Table 1 were investigated according to the method described above are listed in the following Table 2. In order to facilitate the interpretation, the substituents of the investigated compounds were included in the table. Prior art compounds were marked with an asterisk.

Table 2

Decomposition of compounds I:
Half-life (t 1/2) in hours in solution at a pH of 5



(I)

Compound No.	R1-O	R1'	R2	R3	R4	t 1/2(h)
1*	CHF_2CF_2-O	H	CH_3	CH_3O	H	2,1
2	CHF_2CF_2-O	H	CH_3O	CH_3O	H	21
3*	CH_3-O	H	CH_3	CH_3O	H	2,0
4*	CHF_2-O	H	CH_3	CH_3O	H	0,8
5	CHF_2-O	H	CH_3O	CH_3O	H	> 40
6*	CHF_2-O	CH_3O	CH_3	CH_3O	H	2,7
7	CHF_2-O	CH_3O	CH_3O	CH_3O	H	28
8*	-O-CF_2-O-		CH_3	CH_3O	H	3,6
9	-O-CF_2-O-		CH_3O	CH_3O	H	80
10*	CF_3CH_2-O	H	CH_3	CH_3O	H	1,4
11	CF_3CH_2-O	H	CH_3O	CH_3O	H	10,2
12*	CH_3-O	H	CH_3	CH_3O	CH_3	5
13	CHF_2-O	H	CH_3	CH_3O	CH_3O	23
14*	CHF_2CF_2-O	H	H	CH_3O	CH_3	0,9
15	CHF_2CF_2-O	H	H	CH_3O	CH_3O	29

The half-life (t 1/2) is the time in which half of the compound decomposes.

Discussion

The object of the above comparative tests was to compare the chemical stability of compounds of SN 748,591 with the stability of structurally closely related compounds of the prior art. For this purpose pairs of compounds have been selected (1* and 2, 6* and 7, 8* and 9, 10* and 11, 14* and 15) which differ solely with regard to the substitution in the pyridine ring (the prior art compounds * are methoxy/methyl-substituted, whereas the compounds of SN 748,591 are dimethoxy-substituted). The group of compounds 3*, 4* and 5 includes two prior art compounds (3* and 4*), which both are methoxy/methylsubstituted in the pyridine ring, which, however, differ with regard to the substitution in the benzimidazole ring (3* = methoxy, 4* = difluoromethoxy). With regard to the pair of compounds 12*/13, it has to be noted that these compounds differ in two respects: Compound 12* is methoxy-substituted in the benzimidazole, whereas compound 13 is difluoromethoxy-substituted, and in the pyridine ring compound 12* is methoxy/methyl-substituted, whereas compound 13 is dimethoxy-substituted. The connecting link (as in the group 3*, 4* and 5) with difluoromethoxy in the benzimidazole and methoxy/methyl in the pyridine is missing here, but from the comparison of the stability values for 3*, 4* and 5 it can be concluded that the situation with regard to the connecting link should be similar.

The half-life values determined in the comparative tests clearly show that the chemical stability of the compounds of SN 748,591 is significantly greater than the stability of the compounds of the prior art. This greater stability in solution at pH 5 is obtained by the introduction of a second alkoxy substituent in the 3- or 5-position of the pyridine ring in addition to the 4-alkoxy substituent. From this improved stability and the related reduced reactivity at a pH of 5 it can be concluded that the dialkoxy substituted compounds will be more specific than those of the prior art. This combination of substituents fulfills the selection criterion described in the objective.

4. THAT, the comparative test data in Table 2 prove that the compounds of SN 748,591 have stability characteristics which are unexpectedly superior to those of the compounds of the closest prior art.

THAT, it was not foreseeable that the compounds of SN 748,591, which have as an essential structural feature **two** alkoxy groups in the pyridine ring, would show a chemical stability which is so unambiguously superior over known compounds, having only **one** alkoxy group in the pyridine ring.

5. The undersigned Declarant declares further that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signed at Constance, Federal Republic of Germany,
this 22nd day of January, 1987.



(Dr. Uwe Krüger)

Literature

[1] K. Klemm et al., J. Chem. Soc., Chem, Commun. 1986, 125

[2] P. Lindberg et al., J. Med. Chem. 29 (8), 1327 (1986)

[3] D.-J. Reijngoud, J. M. Tager, Biochimica et Biophysica Acta, 472 (1977) 419-449

[4] S. Ohkuma, B. Poole, Proc. Natl. Acad. Sci. USA 75, 3327-3331 (1978)

List of publications

1. NMR-spektroskopische Untersuchungen an Koplexen Aromat/p-Benzochinon
   H.H. Perkampus and U. Krüger
   Zeitschrift für Phys. Chemie Neue Folge, 1966, 48 (5/6), 379 - 382

2. NMR-spektroskopische Untersuchungen am System Pyridin/Benzol-d_6 und Pyridin-N-oxid/Benzol-d_6
   H.H. Perkampus and U. Krüger
   Zeitschrift für Phys. Chemie Neue Folge, 1967, 55 (3/4), 202 - 207

3. Zur chemischen Verschiebung des γ-Protonensignals in α-substituierten Pyridinderivaten
   H.H. Perkampus and U. Krüger
   Chem.Berichte 1967, 100, 1165 - 1168

4. NMR-spektroskopische Untersuchungen an Koplexen von Pyridinderivaten mit Lewissäuren und Protonen
   H.H. Perkampus and U. Krüger
   Berichte der Bunsengesellschaft für physikalische Chemie 1967, 71 (5), 439 - 446

5. π-Elektronendichte und Lage der Protonensignale bei Pyridinderivaten
   H.H. Perkampus and U. Krüger
   Berichte der Bunsengesellschaft für physikalische Chemie 1967, 71 (5), 447 - 451

6. Überführung von 1-Benzylisochinolinen in Berbinium-Salze
   W. Wiegrebe, U. Krüger, H. Reinhart and L. Faber
   Archiv der Pharmazie 301 (1), 50 - 58

7. Untersuchungen über die Eigenassoziationen einiger Nucleosid-Derivate in Lösung
   U. Krüger, H. Breuer, F.M. Abdel Kerim, H.H. Perkampus and K.H. Scheidt
   Zeitschrift für Naturforschung 1968, 23b (10), 1360 - 1366

8. Alkaloide aus Cynanchum vincetoxicum (L.) Pers.
   W. Wiegrebe, L. Faber, H. Brockmann jr, H. Budzikiewicz and U. Krüger
   Justus Liebigs Annalen der Chemie 1969, 721, 154 - 162

9. Solvent Effects on Restricted Rotation in Substituted
3-Amino-Benzisothiazole-S-Dioxides
U. Krüger and H. Hettler
Berichte der Bunsengesellschaft für physikalische Chemie 1969, 73 (1),
15 - 20

10. Indanyl-Isochinoline
W. Wiegrebe, H. Reinhart, H. Budzikiewicz and U. Krüger
Tetrahedron 1969, 25, 2899 - 2907

11. NMR-spektroskopische Untersuchungen über zwischenmolkulare Wechselwirkungen bei Benzolderivaten und Pyrrol
H.H. Perkampus, U. Krüger and W. Krüger
Zeitschrift für Naturforschung 1969, 24b (11), 1365 -1370

12. Synthese und Konfigurationsbestimmung der 3Z,5E-, 3Z,5Z-, 3E,5E-konfigurierten N-Cyclohexyl-6-phenylhepta-3,5-diensäureamide
G. Quinkert, M. Hintzmann, P. Michaelis, P. Jürges and U. Krüger
Angewandte Chemie 1970, 82 (5), 220 - 221

13. Tieftemperatur-spektroskopischer Nachweis zweier konfigurations-isomerer Dienylketene aus 6-Methyl-6-phenylcyclohexa-2,4-dienon
G. Quinkert, B.Bronstert, P. Michaelis and U. Krüger
Angewandte Chemie 1970, 82 (5), 221 - 222

14. Zur Lösungsmittel- und Konzentrationsabhängigkeit der Protonensignale des Methanols
H.H. Perkampus and U. Krüger
Zeitschrift für Phys. Chemie Neue Folge 1969, 67, 159 - 162

15. Eine Farbreaktion der 1-Benzoyl-3,4-dihydro-isochinoline
H. Budzikiewicz and U. Krüger; W.D. Sasse and W. Wiegrebe
Justus Liebigs Annalen der Chemie 1970, 737, 119 -127

16. Electro-Optic Materials for Digital Light Beam Deflectors
U. Krüger, R.Pepperl and U.J. Schmidt
Proc. IEEE 1973, 61 (7), 992 - 1007

17. Formation and reaction of long-lived xanthene dye radicals. I. Photochemical studies on reactions of semi-reduced fluorescein
U. Krüger and R. Memming
Berichte der Bunsengesellschaft für physikalische Chemie 1974, 78 (7), 670 - 678

18. Formation and reaction of long-lived xanthene dye radicals. II. Photochemical reduction of rhodanine B and fluorescein derivatives
U. Krüger and R. Memming
Berichte der Bunsengesellschaft für physikalische Chemie 1974, 78 (7), 679 - 685

19. Formation and reaction of long-lived xanthene dye radicals. III. Spectroelectrochemical studies on the reduction of xanthene dyes.
U. Krüger and R. Memming
Berichte der Bunsengesellschaft für physikalische Chemie 1974, 78 (7), 685 - 692

20. Synthese und physikalisch-chemische Eigenschaften des Antihypertensivums Urapidil
K. Klemm, W. Prüsse and U. Krüger
Arzneim.-Forsch./Drug Res. 1977, 27 (II), 1895 - 1897

21. Synthese und physikalisch-chemische Eigenschaften von Clanobutin
K. Klemm, W. Krastinat and U. Krüger
Arzneim.-Forsch./Drug Res. 1979, 29 (I), 1 - 2

22. In-vitro Methode zur Abschätzung der enteralen Absorption von Clanobutin und anderer Pharmaka
K. Klemm and U. Krüger
Arzneim.-Forsch./Drug Res. 1979, 29 (I), 2 - 11

23. Synthese und physikalisch-chemische Eigenschaften von Lonazolac-Ca, einem neuen Antiphlogistikum/Antirheumatikum
G. Rainer, U. Krüger and K. Klemm
Arzneim.-Forsch./Drug Res. 1981, 31 (I), 649 - 655

24. Long-range anisotropic effects of long-chain amides
H. Budzikiewicz, P.E. Vieth and U. Krüger
Monatsh. Chem. 1981, 112 (6-7) 825 - 840

25. Synthese, physikalisch-chemische Eigenschaften und orientierende pharmakologische Untersuchungen von Budipin und verwandten 4,4-Diphenylpiperidinen
H. Schaefer, G. Hackmack, K. Eistetter, U. Krüger, H.G. Menge and J. Klosa
Arzneim.-Forsch./Drug Res. 1984, 34 (I), 233 - 240

26. Acid Activation of (H^+-K^+)-ATPase inhibiting 2-(2-Pyridylmethylsulphinyl)-benzimidazoles: Isolation and Characterization of the Thiophilic 'Active Principle' and its Reactions
V. Figala, K. Klemm, B. Kohl, U. Krüger, G. Rainer, H. Schaefer,
J. Senn-Bilfinger and E. Sturm
J. Chem. Soc., Chem. Commun. 1986, 125 - 127